Boston Scientific Announces FDA Approval Of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For ... (Medical News Today)
Boston Scientific Corporation (NYSE: BSX) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System. The TAXUS Express Atom Stent is a highly deliverable drug-eluting stent (DES) specifically designed for treating small coronary vessels.

FDA extends review of Lilly blood thinner (The Indianapolis Star)
For a second time, federal regulators say they need more time to review Eli Lilly and Co.'s experimental heart drug, further delaying the launch of the Indianapolis company's most anticipated new product in years.